Quick Answer
Biofrontera Inc. reported Cash and Equivalents of $6.39 million for fiscal year 2025.
Biofrontera Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $6.39M | +8.2% |
| 2024 | $5.91M | +339.7% |
| 2023 | $1.34M | -92.2% |
| 2022 | $17.21M | -29.9% |
| 2021 | $24.55M | +203.8% |
| 2020 | $8.08M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.42M | +18.9% | -52.8% |
| June 30, 2025 | $7.24M | +65.3% | +305.5% |
| March 31, 2025 | $1.78M | -53.2% | -69.8% |
| December 31, 2024 | $5.91M | +339.7% | +105.5% |
| September 30, 2024 | $2.87M | -16.0% | -34.4% |
| June 30, 2024 | $4.38M | -1.7% | +14.7% |
| March 31, 2024 | $3.82M | +193.6% | +184.2% |
| December 31, 2023 | $1.34M | -92.2% | -60.8% |
- Biofrontera Inc. showed an increase of +8.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Biofrontera Inc.’s cash and equivalents has declined by 20.9% (from $8.08 million to $6.39 million).
- The most recent figure is from Biofrontera Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: